Upcoming treatments in Parkinson's disease, including gene therapy

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Rodnitzky, Robert L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Gene therapy; Investigational drugs; Parkinson's disease

Indexed keywords

ADENOVIRUS VECTOR; ANTIPARKINSON AGENT; AROMATIC AMINO ACID; BENSERAZIDE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CERE 120; COGANE; CREATINE; FIPAMEZOLE; GLUTAMATE DECARBOXYLASE; ISRADIPINE; ISTRADEFYLLINE; LEVODOPA; NEURTURIN; PARDOPRUNOX; PIMAVANSERIN; PLACEBO; PRAMIPEXOLE; PRELADENANT; PROSAVIN; RASAGILINE; SAFINAMIDE; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; ADENO ASSOCIATED VIRUS VECTOR; AMINO ACID RECEPTOR BLOCKING AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CALCIUM CHANNEL BLOCKING AGENT; DROXIDOPA; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; LENTIVIRUS VECTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; UNINDEXED DRUG;

ARTICLE; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSKINESIA; GEL; GENE THERAPY; GENE TRANSFER; HUMAN; HYPOTENSION; IMMEDIATE DRUG RELEASE; LOW DRUG DOSE; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROMODULATION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SINGLE DRUG DOSE; SYMPTOM; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; CONTROLLED DRUG RELEASE; DRUG FORMULATION; EXCITOTOXICITY; HYPERTENSION; NONHUMAN; ORTHOSTATIC HYPOTENSION; SUBTHALAMIC NUCLEUS; VIRAL GENE THERAPY;

EID: 84858680497     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70014-1     Document Type: Article

References (20)

1. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson;s disease. N Engl J Med 1990 322 [21], 1526-28.
2. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989 Sep;39(9):1219-21.
3. Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998 Sep;13(5):851.
4. Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011 E-pub.
5. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005 Jan 25;64(2):216-23.
6. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, doubleblind, randomised trial. Lancet Neurol 2011 Mar;10(3):221-29.
7. Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, et al. Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov Disord 2011 E-pub.
8. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008 Mar;18(Suppl 1): 25-29.
9. Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008 Mar;18(Suppl 1):19-24.
10. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010 Mar;35(4):881-92.
11. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008 May;31(3):141-50.
12. Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, et al. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord 2010 Dec 15;25(16):2863-66.
13. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010 Oct 6;2(52):52-73.
14. Lewitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a doubleblind, sham-surgery controlled, randomised trial. Lancet Neurol 2011 Apr;10(4): 309-19.
15. Marks WJ, Jr., Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010 Dec;9(12):1164-72.
16. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011 Jan;26(1):27-36.
17. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009 Nov 17;73(20):1662-69.
18. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010 Sep;18(9):1731-1735.
19. Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009 Oct 14;1(2):2-4.
20. de Ynigo-Mojado L, Martin-Ruiz I, Sutherland JD. Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS One 2011;6(6): e21352.